Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) commonly co‐occur. T2DM increases the risk for AD by approximately twofold. Animal models provide one means of interrogating the relationship of T2DM to AD and investigating brain insulin resistance in the pathophysiology of AD. Animal models show that persistent hyperglycaemia results in chronic low‐grade inflammation that may contribute to the development of neuroinflammation and accelerate the pathobiology of AD. Epidemiological studies suggest that patients with T2DM who received treatment with specific anti‐diabetic agents have a decreased risk for the occurrence of AD and all‐cause dementia. Agents such as metformin ameliorate T2DM and may have other important systemic effects that lower the risk of AD. Glucagon‐like peptide 1 (GLP‐1) agonists have been associated with a decreased risk for AD in patients with T2DM. Both insulin and non‐insulin anti‐diabetic treatments have been evaluated for the treatment of AD in clinical trials. In most cases, patients included in the trials have clinical features of AD but do not have T2DM. Many of the trials were conducted prior to the use of diagnostic biomarkers for AD. Trials have had a wide range of durations and population sizes. Many of the agents used to treat T2DM do not cross the blood brain barrier, and the effects are posited to occur via lowering of peripheral hyperglycaemia and reduction of peripheral and central inflammation. Clinical trials of anti‐diabetic agents to treat AD are ongoing and will provide insight into the therapeutic utility of these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Self-citationNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“…(Hardy & Higgins, 1992; Hyman et al., 2012), neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986; Serrano-Pozo et al., 2011), and chronic neuroinflammation, or a sustained immune response in the brain, that promotes and accelerates both Aβ and…”
BackgroundHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“The pathological hallmarks of AD include amyloidbeta (Aβ) protein plaques composed of fibrillar Aβ (Hardy & Higgins, 1992; Hyman et al., 2012), neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986; Serrano-Pozo et al., 2011), and chronic…”
BackgroundVariant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Self-citationOxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 10×
“Chronic peripheral and inflammation induced by DM and obesity can cause BBB breakdown and permeability to infiltrating macrophages, leading to exacerbation of the immune response in the brain, disruption of glial and neuronal cell integrity, impaired hormonal function, increased insulin insensitivity and impaired cogn…”
BackgroundInfluentialTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 3×
“1.6.1 | Apolipoprotein E APOE is a protein that is involved in lipid and cholesterol binding and transport and is the most common genetic risk factor for AD (Corder et al., 1993; Kim et al., 2009; Strittmatter et al., 1993).”
BackgroundInfluentialBrain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551 · cited 1×
“…from the periphery and entry of peripheral inflammatory cells through a compromised BBB (Li et al., 2018; Pugazhenthi et al., 2017; Ransohoff, 2016; Zlokovic, 2008); both diabetes and obesity exhibit chronic low-grade inflammation in association with insulin resistance (Osborn & Olefsky, 2012).”
BackgroundObese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice
Coleman, D. L. (1978) · Diabetologia · doi:10.1007/bf00429772 · Cited by 1,307
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · cited 1×
“GSK-3β can contribute to development of NFTs (Beurel et al., 2015; Hanger et al., 1992; Mandelkow et al., 1992) and Aβ plaque formation (Beurel et al., 2015; Hurtado et al., 2012; Phiel et al., 2003).”
BackgroundThe GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
The blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172 · cited 1×
“The invasion of leukocytes releases proinflammatory cytokines that exacerbate AD pathology including neuronal damage and death (Kinney et al., 2018; Varatharaj & Galea, 2017).”
BackgroundApolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · cited 10×
“Liraglutide prevented tau hyperphosphorylation in the hippocampus of db/db mice via activating insulin signalling pathways and suppressed GSK-3β activation (Ma et al., 2015).”
BackgroundInfluentialOBESE, A NEW MUTATION IN THE HOUSE MOUSE*
INGALLS, A. M., DICKIE, M. M., & SNELL, G. D. (1950) · Journal of Heredity · doi:10.1093/oxfordjournals.jhered.a106073 · Cited by 1,090
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“Furthermore, approximately 80% of individuals with AD have insulin resistance or abnormal fasting glucose levels (Janson et al., 2004).”
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
Oxidative Stress and the Pathogenesis of Alzheimer's Disease
Zhao, Y., & Zhao, B. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/316523 · Cited by 855
Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793 · cited 1×
“1.7 | Animal model treatment-related insights 1.7.1 | Insulin Insulin is a hormone produced primarily by pancreatic β cells (Rorsman & Ashcroft, 2018), although it has been shown that neurons can produce insulin (Bl azquez et al., 2014; Gray et al., 2014).”
MethodInfluentialHanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · cited 1×
“GSK-3β can contribute to development of NFTs (Beurel et al., 2015; Hanger et al., 1992; Mandelkow et al., 1992) and Aβ plaque formation (Beurel et al., 2015; Hurtado et al., 2012; Phiel et al., 2003).”
BackgroundKitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697 · cited 1×
“LPS-induced CNS inflammation in 3xTg-AD mice showed significant increase of tau hyperphosphorylation via cdk5 (Kitazawa et al., 2005).”
BackgroundCommon neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease
Pugazhenthi, S., Qin, L., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.04.017 · Cited by 697
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1×
“GLP-1R can activate the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway leading to protection against apoptosis and inhibition of pro-inflammatory cytokines (Farilla et al., 2003; Grieco et al., 2019; Tramutola et al., 2017; Yang et al., 2018).”
BackgroundRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 1×
“A tau transgenic (Tg) mouse model (hTau mice) lacking CX3CR1 exhibited enhanced tau phosphorylation and aggregation associated with microglial activation, as well as behavioural impairments (Bhaskar et al., 2010; Bolos et al., 2017).”
BackgroundAge, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin Resistance
Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J., Barrett, T., Kim, J. K., & Davis, R. J. (2008) · Science · doi:10.1126/science.1160794 · Cited by 604
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 5×
“GLP-1 reduces oxidative stress, is involved in autophagy regulation and exhibits anti-inflammatory protective functions (e.g., anti-inflammatory signalling) in the CNS (Li et al., 2009).”
BackgroundInfluentialAmyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 1×
“Soluble Aβ oligomers can impair insulin signalling via downregulation of IRs on neurons (Zhao et al., 2008).”
BackgroundMolecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570 · cited 1×
“Glucotoxicity can result in cell injury to hepatocytes and insulin-producing pancreatic β cells via mitochondrial oxidative stress and mitochondrial dysfunction (Lee, Lee, et al., 2011; Mota et al., 2016).”
BackgroundHeneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Self-citationGenetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5476-05.2006 · Cited by 524
Lee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522 · cited 1×
“…the cortex and hippocampus at approximately 3–4 months of age (Radde et al., 2006), followed by reactive gliosis and proinflammatory cytokine release (Lee et al., 2010; Radde et al., 2006), synaptic loss (Bittner et al., 2012), neuronal loss in the dentate gyrus (Rupp et al., 2011), hippocampal…”
BackgroundGlycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau
Mandelkow, E.-M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., Vandenheede, J. R., & Mandelkow, E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81496-9 · Cited by 515
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Metformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450 · cited 1×
“Some classes of T2DM therapies—metformin and GLP-1 agonists—reduce peripheral inflammation and this may contribute to both their anti-diabetic properties and the reduction in AD incidence reported with their use (Lee & Jun, 2016; Saisho, 2015).”
BackgroundDiabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis
Lu, F.-P., Lin, K.-P., & Kuo, H.-K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004144 · Cited by 398 · cited 1×
“Type 2 diabetes mellitus (T2DM) can confer a 1.5-fold to fourfold increase in lifetime risk for AD (Lu et al., 2009; Mehla et al., 2014).”
BackgroundInfluentialCraft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · cited 1×
“APP/PS1 mice administered pioglitazone showed reduced microglia and astrocyte activation and reduced Aβ plaques in the hippocampus (Mandrekar-Colucci et al., 2012).”
BackgroundCraft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326 · cited 1×
“Pioglitazone increased microglial Aβ phagocytosis in the hippocampus in an AD mouse model (Yamanaka et al., 2012).”
BackgroundGenes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Van Der Heide, L. P., Kamal, A., Artola, A., Gispen, W. H., & Ramakers, G. M. J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03269.x · Cited by 278
Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice
Li, J., Deng, J., Sheng, W., & Zuo, Z. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.002 · Cited by 260
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253 · cited 2×
“GLP-1R agonist agents (e.g., exenatide, lixisenatide, liraglutide, semaglutide, etc.) lower glucose levels and reduce cognitive deficits observed in T2DM (Aroda, 2018; Gomez-Peralta & Abreu, 2019; Grieco et al., 2019).”
BackgroundAbsence of CX3CR1 impairs the internalization of Tau by microglia
Bolós, M., Llorens-Martín, M., Perea, J. R., Jurado-Arjona, J., Rábano, A., Hernández, F., & Avila, J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0200-1 · Cited by 231 · cited 1×
“A tau transgenic (Tg) mouse model (hTau mice) lacking CX3CR1 exhibited enhanced tau phosphorylation and aggregation associated with microglial activation, as well as behavioural impairments (Bhaskar et al., 2010; Bolos et al., 2017).”
BackgroundGeldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218 · cited 4×
“GLP-1R agonist agents (e.g., exenatide, lixisenatide, liraglutide, semaglutide, etc.) lower glucose levels and reduce cognitive deficits observed in T2DM (Aroda, 2018; Gomez-Peralta & Abreu, 2019; Grieco et al., 2019).”
BackgroundInfluentialInsulin Regulates Brain Function, but How Does It Get There?
Gray, S. M., Meijer, R. I., & Barrett, E. J. (2014) · Diabetes · doi:10.2337/db14-0340 · Cited by 206 · cited 1×
“1.7 | Animal model treatment-related insights 1.7.1 | Insulin Insulin is a hormone produced primarily by pancreatic β cells (Rorsman & Ashcroft, 2018), although it has been shown that neurons can produce insulin (Bl azquez et al., 2014; Gray et al., 2014).”
MethodInfluentialThe impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185 · cited 1×
“The HFD and obesity have been shown to increase neuroinflammation (Spagnuolo et al., 2015), neurodegeneration (Mazon et al., 2017; Pugazhenthi et al., 2017) and cognitive decline (Balasubramanian et al., 2021; Nguyen et al., 2014) that are consistent with AD.”
A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease
Kyrtata, N., Emsley, H. C. A., Sparasci, O., Parkes, L. M., & Dickie, B. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.626636 · Cited by 171
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
Zhou, J., Yu, W., Zhang, M., Tian, X., Li, Y., & Lü, Y. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02748-x · Cited by 139
Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., MacDonald, C., Aboagye, A. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0889-12.2012 · Cited by 126
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Barini, E., Antico, O., Zhao, Y., Asta, F., Tucci, V., Catelani, T., Marotta, R., Xu, H., & Gasparini, L. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0082-7 · Cited by 126
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Cai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108
Solmaz, V., Çınar, B. P., Yiğittürk, G., Çavuşoğlu, T., Taşkıran, D., & Erbaş, O. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.024 · Cited by 96
Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease
Barone, E., Tramutola, A., Triani, F., Calcagnini, S., Di Domenico, F., Ripoli, C., Gaetani, S., Grassi, C., Butterfield, D. A., Cassano, T., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1231-5 · Cited by 86 · cited 1×
“…for 2 months, demonstrated improved memory (in novel object recognition task and MWM), reduced depression-like behaviour (via tail suspension and forced swim tests) and decreased hyperphosphorylated tau, Aβ oligomers and 3- nitrotyrosine in the frontal cortex and hippocampus (Barone et al., 2019).”
BackgroundObesity, Insulin Resistance, and Alzheimer's Disease
Hildreth, K. L., Van Pelt, R. E., & Schwartz, R. S. (2012) · Obesity · doi:10.1038/oby.2012.19 · Cited by 86 · cited 1×
“Metabolic syndrome is composed of insulin resistance, obesity, hypertension, cardiovascular disease and dyslipidaemia which increase the risk of AD beyond the risk conferred by T2DM (Hildreth et al., 2012; Verdile et al., 2015).”
BackgroundDevelopment of clinical trials to extend healthy lifespan
Justice, J. N., Niedernhofer, L., Robbins, P. D., Aroda, V. R., Espeland, M. A., Kritchevsky, S. B., Kuchel, G. A., & Barzilai, N. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000159 · Cited by 84
The role of APOE in transgenic mouse models of AD
Balu, D., Karstens, A. J., Loukenas, E., Maldonado Weng, J., York, J. M., Valencia-Olvera, A. C., & LaDu, M. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134285 · Cited by 81
Cited by
Skrzypczak-Wiercioch, A., & Sałat, K. (2022) · Molecules · doi:10.3390/molecules27175481 · Cited by 406
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330
“The exact cause of AD is not fully understood; there is therefore currently no effective treatment despite the large number of clinical studies that have been performed [4].”
BackgroundKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
State of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0814 · Cited by 70
Metadata
- Authors
- Cummings, J., Ortiz, A., Castellino, J., & Kinney, J.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2022-02-23
- Volume
- 56
- Issue
- 9
- Pages
- 5727-5757
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W4210423403
- Cited by
- 48
- References
- 74
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.